Forest CEO: Aptalis a `Compelling Opportunity'

Jan. 8 (Bloomberg) -- Brent Saunders, chief executive officer of Forest Laboratories Inc., talks about the company's agreement to acquire Aptalis Pharma for $2.9 billion in cash. Aptalis is a closely held company whose shareholders include investment firm TPG Capital. Saunders speaks with Betty Liu on Bloomberg Television's "In the Loop." (Source: Bloomberg)
What You Need To Know: The Morning Brief
40:31 - Bloomberg's Jonathan Ferro briefs you on the day's tops stories.
  • Africa's Richest Man Eyes London Listing
  • Tsipras Reshuffles Negotiation Team, Sidelines Varoufakis
  • Ola: the App Driving India’s Taxi Industry